| Similar Articles |
|---|
 |
The Motley Fool
July 5, 2005
Brian Gorman |
Bausch & Lomb Eyes China The firm's latest purchase will add geographic diversity to its pharmaceutical business. Investors, take note.   |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |
The Motley Fool
October 27, 2005
Brian Gorman |
Bausch & Lomb's Cloudy Quarter An accounting scandal at a Brazilian subsidiary clouded third-quarter results, but the underlying business still looks good. Investors, take note. |
The Motley Fool
April 11, 2006
Rick Aristotle Munarriz |
Bausch & Lomb Sees Eye to Ay The contact lens specialist gets tripped up over its potentially infected ReNu brand. Bausch & Lomb's stock took a 9% hit in after-hours trading on the news. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Do The Eyes Have It for Bausch & Lomb? New product launches and extensions coupled with improving margins should boost results. Investors, take note. |
The Motley Fool
April 22, 2004
Brian Gorman |
Bausch & Lomb Delivers The 150-year-old eye-care company's sales aren't sizzling, but its profitability is improving. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
The Motley Fool
May 17, 2007
Matt Koppenheffer |
Bausch & Lomb: How Much Is Too Much? Private equity's Warburg Pincus agrees to take the eye-care company private. Investors, take note. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
The Motley Fool
March 12, 2009
Robert Steyer |
A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another. |
The Motley Fool
March 30, 2011
Brian Orelli |
Valeant Vultures Will Cephalon manage to rebuff Valeant's advances? |
Chemistry World
September 6, 2012
Andrew Turley |
Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products. |
Chemistry World
November 24, 2014
Andy Extance |
Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis. |
The Motley Fool
November 2, 2005
Stephen D. Simpson |
AMO Focuses on the Giants Advanced Medical Optics sets its sights on the big players in eye care. Will David be able to take on the Goliaths? Investors, take note. |
BusinessWeek
June 16, 2011
Mider & McCracken |
M&A: The Markets Love a Buyer Contrary to conventional wisdom, the announcement of an acquisition is likely to lift the stock price of the company doing the buying. |
The Motley Fool
March 3, 2009
Brian Orelli |
Pfizer Eyes Generic Growth Two partnerships in one day? Oh my! |
The Motley Fool
May 31, 2007
Billy Fisher |
Not Seeing 20/20 at Advanced Medical Optics The company recalls a contact lens solution that might be linked to a rare infection. Investors, take note. |
The Motley Fool
October 12, 2006
Tim Hanson |
5 Turnaround Stocks These stocks are down, but not out: Bausch & Lomb... Compucredit... Intersections... Syneron Medical... etc. |
Pharmaceutical Executive
November 1, 2005
Sara Calabro |
Valeant Pharmaceuticals is Soldiering On Valeant Pharmaceuticals' new CEO Tim Tyson restructures the company after legal and financial troubles. |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Cooper's Bleary Performance Missteps in strategy and operations for the contact lens company are coming home to roost. As is almost always the case with turnarounds, this is an idea with above-average risk, so don't make the mistake of underestimating the odds that things could get even worse. |
